Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study
Clinical Research in Cardiology · 2024
DOI: 10.1007/s00392-024-02382-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research in Cardiology, 2024. Verfasst von Sang Heon Suh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Ko…. Hauptthemen laut MEDLINE: Osteoprotegerin, Biomarkers, Ventricular Dysfunction, Left, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Research Program funded by the Korea Disease Control and Prevention Agency, by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT).
Abstract (Originalsprache)
Background
Heart failure with preserved ejection fraction (HFpEF) is a major cause of mortality in patients with chronic kidney disease (CKD), and diagnosis is challenging. Moreover, no specific biomarker for HFpEF has been validated in patients with CKD. The present study aimed to investigate the association between serum osteoprotegerin (OPG) levels and the risk of left ventricular diastolic dysfunction (LVDD), a surrogate of HFpEF, in patients with pre-dialysis CKD.
Methods
A total of 2039 patients with CKD at stage 1 to pre-dialysis 5 were categorized into quartiles (Q1 to Q4) by serum OPG levels, and were cross-sectionally analyzed. The study outcome was LVDD, which was operationally defined as the ratio of early transmitral blood flow velocity to early diastolic velocity of the mitral annulus (E/e’) > 14.
Results
In the analysis of baseline characteristics, higher serum OPG levels were clearly related to the risk factors of HFpEF. A scatter plot analysis revealed a moderate correlation between serum OPG levels and E/e’ ( R = 0.351, P < 0.001). Logistic regression analysis demonstrated that the risk of LVDD in Q3 (adjusted odds ratio 2.576, 95% confidence interval 1.279 to 5.188) and Q4 (adjusted odds ratio 3.536, 95% confidence interval 1.657 to 7.544) was significantly higher than that in Q1.
Conclusions
Elevated serum OPG levels are associated with the risk of LVDD in patients with pre-dialysis CKD. The measurement of serum OPG levels may help the diagnosis of LVDD, which is an important echocardiographic feature of HFpEF. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
- Division of Nephrology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
- Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 03181, Republic of Korea.
- Department of Internal Medicine, Chonnam National University Medical School and Chonnam National University Hospital, 42 Jebongro, Gwangju, 61469, Korea. skimw@chonnam.ac.kr.
Förderung
- the Research Program funded by the Korea Disease Control and Prevention Agency
- by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
Zitieren
APA
Suh, S. H., Oh, T. R., Choi, H. S., Kim, C. S., Bae, E. H., Ma, S. K., Oh, K. H., Jung, J. Y., Hyun, Y. Y., Kim, S. W., & Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators (2024). Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02382-w
Vancouver
Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, et al. Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study. Clinical Research in Cardiology. 2024. doi:10.1007/s00392-024-02382-w
BibTeX
@article{Suh2024,
author = {Suh, Sang Heon and Oh, Tae Ryom and Choi, Hong Sang and Kim, Chang Seong and Bae, Eun Hui and Ma, Seong Kwon and Oh, Kook-Hwan and Jung, Ji Yong and Hyun, Young Youl and Kim, Soo Wan and Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators, Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) Investigators},
title = {Circulating osteoprotegerin as a cardiac biomarker for left ventricular diastolic dysfunction in patients with pre-dialysis chronic kidney disease: the KNOW-CKD study},
journal = {Clinical Research in Cardiology},
year = {2024},
doi = {10.1007/s00392-024-02382-w}
}
EUVIMED